

Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

Claims 1-11. (Cancelled)

A1 12. (Currently Amended) A method of reducing injury to tissue an organ in vivo exposed to an ischemic or ~~an~~ hypoxic condition, comprising administering to the tissue organ a ψ RACK peptide.

13. (Currently Amended) The method of claim 12, wherein said administering occurs prior to exposing the tissue organ to said ischemic or hypoxic condition.

14. (Original) The method of claim 13, wherein said administering prior to said ischemic or hypoxic condition is for between about 1-180 minutes.

A2 15. (Currently Amended) The method of claim 12, wherein said administering occurs after exposing the tissue organ to said ischemic or hypoxic condition.

16. (Currently Amended) The method of claim 15, wherein said administering after exposure to said ischemic or hypoxic condition occurs for between about 1-180 minutes ~~after said ischemic or hypoxic condition~~.

17. (Currently Amended) The method of claim 12, wherein said administering occurs during exposure of the tissue organ to said ischemic or hypoxic condition.

18. (Original) The method of claim 12, wherein said administering includes administering a peptide having a sequence identified as SEQ ID NO:2.

19. (Withdrawn)

20. (Original) The method of claim 12, wherein said administering includes administering a ψ eRACK peptide linked to a moiety effective to facilitate transport across a cell membrane.

21. (Original) The method of claim 12, wherein the moiety is selected from the group consisting of a Tat-derived peptide (SEQ ID NO:5), an Antennapedia carrier peptide (SEQ ID NO:3), and a polyarginine peptide.

A3
22. (Currently Amended) The method of claim 12, wherein said administering includes administering the peptide by a route selected from the group consisting of intravenous intravenous, parenteral, subcutaneous, inhalation, intranasal, sublingual, mucosal, and transdermal.

23. (Cancelled)

24. (Cancelled)

A4
25. (Currently Amended) The method of claim 23 or 24 12, wherein said organ is selected from the group consisting of heart, lung, liver, brain, and kidney.

26. (Currently Amended) The method of claim 24 12, wherein said administering is by infusion through coronary arteries to an intact heart.